{"preliminary_commentary":{"by_channel":{"youtube":14,"podcast":10,"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05120349\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ADAURA 2","nct_id":"NCT05120349","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adaura-2-nct05120349. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ADAURA2","arms":[{"description":"Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)","label":"Osimertinib","type":"EXPERIMENTAL"},{"description":"Matching placebo for osimertinib, orally, once daily","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-11-01","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":390,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["AZD9291; TAGRISSO"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-06","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-08-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS) in high-risk stratum","timeFrame":"From date of randomisation up to approximately 10 years"}],"references":[{"citation":"Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18.","pmid":"40311309","type":"DERIVED"}],"start_date":{"date":"2022-02-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","url":"https://clinicaltrials.gov/study/NCT05120349"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adaura-2-nct05120349"}